Day traders dont have room to make those kind of mistakes. A good day trader would have made anywhere from .025 to .04 cents easy. Thats $400 for a 10k lot pre commission.
Yesterday was the best clue for a daytrader for just today. $400 x 30 days = $12,000 mo.
Day trading beats working for Mcdonald. !!!!!!!!!! Eventhough he was short, he could have gone long for just 1 day. You couldnt have gotten a better clue than yesterday. No, i´m not a daytrader, dont have the capital for that.
Mitch, i do believe dará will have a nice run-up prior to the eps report release on May. A lot of people are anticipating good results due to the effect of the Mission and Raintree deals. Mission will have 3 exact months impact on eps due to start date of January 1, 2014 and Raintree will have 2 months of eps based on pr. If sales force is well trained with hungry reps and the Raintree entity has a good demand for their oncology practice needing our drugs, eps could be a pleasenat suprisse. So even with a r/s, i´m saying its still company specific. If enough people who cast votes on the pps are positive on the outlook, the pps will move up regardless of r/s. In the end it is a voting machine. The majority talks, the minority listens. I hope to be in the majority camp, otherwise ummmm, never mind.
Hi lag, that is really not a good comparison. First, in year 2000 dará had ZERO revenues. They probably had NO approved drugs, but NOW has 3 fda approved drugs. In year 2000 dará had NO contracts with selling partners. If you were in year 2000 with dará, you were looking at no cash register for year 2001, 2002, etc. Dara has a cash register now just not yet profitable. A lot of high flying technology stocks also have tremendous revenue but No profits. KRN5500 was probably not where it is today in terms of trial. Correct me if i´m wrong on this. So dará is actually more valuable today than it was in year 2000. Even if krn5500 is removed, the 3 drugs will still bring in revenue and thats Worth something even if unprofitable. Some other bio could be interested in this company. SPPI has a model that only buys approved drugs, they do no developement or very little inhouse. Depomed is also a small bio that has a snack for small acquisition like SPPI. There are others. It isnt the end of the world for this stock. It is high risk, high reward stock. Not BMY or JNJ. Those stocks have very little risk even if a trial blows up.
I introduce you to cbrx a r/s that did NOT drift down, actually went up immediately after, maintained and still is priced higher than the day of r/s. So its all company specific. dará has revenues and approved drug and the revenue is gaining momentum. It just needs time.
lag: fair reasoning if odd is approved and you not in. You can always wait for your proper entry point. As for me, i´m just tired of hearing this odd approval thing. The company should sell itself and we can all move along to other better things. thanks for your reply.
lag 49 out of 50 times, it does not work.
It worked with cbrx. cbrx actually went up immediately after r/s and maintained that path. It gave back a little, but still way above r/s. So you got your 1 out of 50 right. I dont own cbrx as its patent expiration is near. However, it still remains to be seen if this stock can pull a cbrx stunt. It does pull in revenue and has a big potential on krn5500. Also taking soooo long to get fda odd is telling me it might not, and if it doesnt get odd, krn5500 could put the company into play as a lock, stock and barrel buyout or merger solely for krn5500 and not for the other 3 drugs. I already gave up on odd, counting on some bigger pocket pharma interested in krn5500. I read pfizer which was running out of patents bought an experimental one for their pipeline. A big pharma with deep pocket doesnt have to worry about funding the trials nor the credits if what they buy can overcompesate for its acquisition. Just me keeping an open mind.
Also dará was flat last 2 hours, it appears selling has dried up. If i was a short, i would seriously consider covering pre-mkt or right after the opening bell. Dara executives will most likely shop the company as its is an investor conference. jmo.
How many times can you run around a football field without stopping for water and breath? Its been in the toilet for 9+ months, with an impressive 1 month performance since mid Dec 2013. You will see your $1.00+ You see, i´m counting on mameen the resident magician to pull a rabbit out of the hat. Mameen the joker makes my day in this depressing stock less depressing. lol.
You´re not mistaken. It is as rory pointed out. Read his msg. Nobody wants a r/s. Not investors, not company, not makers. If r/s happened, low vol would not stir enough public interest in the company, stock would become more obscure, nobody makes $$. Not even shorts will make $$, low vol = difficult trading profits. The pricing engine would stall and it becomes dead $$. I´m in one oil driller now that dont make a profit and wont go bankrupt, and am stuck. It is for the benefit for ALL that the stock move up even for shorts, if things dont work out, they can short again. Right now, they are bleeding. The pendulem swings both ways. Rent this old movie out, if available. The Pit and the Pendulem with actor Vincent Price. Great for horror movie fans. Maybe difficult to obtain as it is a classic back to the 1960´s. For now, shorts will sweat it out like longs did, but eventually the Pendulem will go the other way. Pendulem is never fixed. Enjoy the long run-up as it happens, rethink your exit if you havent got one. Shorts will live to earn $$ another day. They just have to wait like vultures. No r/s in Feb, Maybe yes, maybe no in May. There are other factors, depends.
Here it is. I went back to Dec 3 as a consolidation phrase. Add vol from Dec 3 to yesterday = 17280400 + vol today 1015066 = 18295466. Take 18.2 m divy by 25.6 m = 71.21% of the current float has turned over and all these are new owners. I came up with an average cost basis ea. new owner paid and it averaged out to be about .54 cents. Some paid more, some paid less. With 71.21% new owners, add those who are still in at higher pps, add in those institutions who did not sell, and you come up with very few people willing to sell. If 71.21% are new owners, that means the rest is in the hands of people who paid higher and the institutions to make 100% total. Those who bought very low in the mid .40ish are proby gone, sold for profit during the run up. So very few willing to sell here, not too much too gain, only razon thin profits unless another run up.
That is why the stock hung close to .54 Those who bought at .60 are locked in, those underwater wont sell, those new at avg .54 wont sell yet. Anybody trying to sell for profit only makes anywhere from .03 to .05 tops. eom.
There wont be too much stop losses for current longs to deal with unless ( see lower ). Very few if any, and if they do exercise their stops, they are on razor thin profits, probably no more than .03 cents profits based on pps that went up to .60 cents. Only if it goes thru the roof again, will you see stops again. Either way the cost basis has gone up for all newcomers. Actually i´m anticipating it will do another go thru the roof so new stops will happen, but a back and fill process is healty. If you standby, i will show my math. Any good press release will help the climb.